Galcanezumab (Emgality) Gets FDA OK for Cluster Headache Megan Brooks June 04, 2019 The US Food and Drug Administration (FDA) has approved the calcitonin gene-related peptide (CGRP) antagonist galcanezumab-gnlm (Emgality, Eli Lilly […]
Abstract Submission is now open For submitting your abstract, click Here.
EHF Announcements Dear all, It was a pleasure meeting most of you last week during congress in Athens – we would like to take the opportunity to invite you to […]
IHS – Short Stay Scholarships Initiative for Improving Headache Practice, Research and Education in Developing Countries The IHS Board of Trustees, together with the IHS Juniors Group, welcomes applications for […]
Background and scope of the school Globally, headache has been reported as the 7th cause of disability. This scientific meeting provides the most useful information on most primary and some secondary […]